Northrop Grumman Corporation Q2 FY26 Earnings Analysis

Published 29 May 2026 | Aerospace and Defense | Market Cap: ₹79.4K Cr

Price

559.29

Market Cap

₹79.4K Cr

P/E Ratio

17.5

Revenue Rank

Rank 4

Margin Rank

Rank 3

Earnings Summary

- Mid-single-digit sales growth expected for the full year 2026, supported by a near-record $96 billion backlog providing over 2 years of sales coverage. - Mid-single-digit sales growth expected for 2026, with full-year sales guidance reaffirmed between $43.5 billion and $44 billion.

📊 Revenue & Sales Performance

Rank 4

- Mid-single-digit sales growth expected for the full year 2026, supported by a near-record $96 billion backlog providing over 2 years of sales coverage. - Multiple new bidding opportunities could drive higher sales growth beyond mid-single digits. - Accelerated ramp-up expected in missile components production, especially solid rocket motors, contingent on contract awards. - International sales pipeline growing, with long-term potential to become a key contributor, though international contracts typically have longer cycles. - Sentinel program projected to grow at low double digits in 2026, moving toward 10% of company revenue over time. - B-21 program nearing 10% of revenue, expected to exceed that in coming years with accelerated production. - Weapons business (including missile defense) nearing 10% of sales, anticipated to be one of the fastest-growing segments. - Overall, growth driven by strong demand across missile defense, munitions, B-21, and Sentinel programs, plus emerging international opportunities.

📈 Profitability & Margins

Rank 3

- Mid-single-digit sales growth expected for 2026, with full-year sales guidance reaffirmed between $43.5 billion and $44 billion. (Page 4) - Sentinel program expected to grow low double digits this year and aim toward 10% of total revenue over time. (Page 8) - B-21 program nearing 10% of revenue and expected to exceed 10% over the next several years with accelerated production. (Page 8) - Weapons business close to 10% of sales, anticipated to be one of the fastest-growing segments, driven by munitions and new programs. (Page 8) - Operating margin projected in the low to mid-11% range for 2026, with expected margin improvements through the year due to production timing and mix. (Page 4) - EPS for Q1 2026 was $6.14, up substantially from the prior year, driven by higher sales and operating income. (Page 4) - Free cash flow guidance maintained at $3.1 billion to $3.5 billion despite higher capital investments. (Page 4) - Future margin expansion is possible as programs mature and manufacturing capabilities improve, subject to competitive environment. (Page 9)

🏗️ Capital Expenditure Plans

Yes

- $200 million CapEx planned for 2026 to support increased production capacity on the B-21 program. - Majority of capital expenditures for B-21 expected in 2027, 2028, and 2029, largely to be completed this decade. - Investment in modernizing solid rocket motor (SRM) and munition technologies totaling over $2 billion made in recent years, with further production expansion completing by 2027. - New production facilities for weapons business are modular and adaptable to flex with demand. - Company investing approximately $2.5 billion for B-21 production ramp-up, alongside customer funding from reconciliation package. - Opened a new facility specifically for accelerating radar production to meet program requirements, including tooling and workforce training completed. - CapEx investments aimed at scaling capacity to meet growing demand, supporting sales growth and long-term profitability.

💰 Fundraising & Capital Structure

No information

- In Q1, the company repaid $527 million of fixed rate debt, ending the quarter with over $2 billion in cash on hand, indicating no immediate need for new debt financing. - Capital expenditures are planned to increase to $1.85 billion in 2026, primarily to support increased production capacity, especially for the B-21 program. - The company did not announce any new fundraising activities through debt or equity. - Free cash flow guidance for 2026 remains strong at $3.1 billion to $3.5 billion, with efforts underway to offset impacts from increased capital investments. - No mention was made of plans for issuing new equity or additional debt in the near future. - The company appears focused on funding growth internally through cash flow and managing existing capital allocations.

📋 Order Book & Pipeline

Yes

- Northrop Grumman's backlog stands at approximately $96 billion, providing over 2 years of sales coverage. - The company continues to see strong bookings, reinforcing growth prospects into next year. - Reconciliation dollars from recent defense budgets are starting to flow into contracts in 2026. - There are numerous new bidding opportunities underway, including international and U.S. defense programs. - The company is working to convert a robust international pipeline into firm orders, though international contracts tend to have longer cycles. - The 2027 defense budget request of $1.5 trillion, including increased funding for key programs like B-21 and Sentinel, indicates sustained demand. - Long-term demand signals and structured production frameworks with the Department of Defense support continued backlog growth. - Awards such as Lot 4 LRIP for B-21 and MDA awards (e.g., GPI) add to confirmed orders, with some contract decisions expected in Q3 2026.

Key Metrics

Revenue

Rank 4

Margin

Rank 3

Capex

Yes

Fundraise

No information

Order Book

Yes

Frequently Asked Questions

What were Northrop Grumman Corporation Q2 FY26 results?

- Mid-single-digit sales growth expected for the full year 2026, supported by a near-record $96 billion backlog providing over 2 years of sales coverage. - Mid-single-digit sales growth expected for 2026, with full-year sales guidance reaffirmed between $43.5 billion and $44 billion.

What is Northrop Grumman Corporation share price analysis?

Northrop Grumman Corporation currently shows a neutral. The stock trades at a P/E of 17.5 with a market cap of $79,438. Investors should review the full earnings analysis for detailed insights.

Is Northrop Grumman Corporation planning capital expenditure?

- $200 million CapEx planned for 2026 to support increased production capacity on the B-21 program.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.